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ABSTRACT 
The effect of 6-chloro-2,3,4,5-tetrahydro-3-methyi-1-H-3-benza-
zepine (SKF 86466), a selectlve nonimldazoline alpha-2 adreno-
ceptor antagonlst, on hippocampal re1ease of norepinephrine and 
dopamlne in conscious rats was lnvestigated by /n vlvo mlcrodi-
alysis and high-pressure liquid chromatography. Additionally, 
extracellular concentrations of hippocampal dopamine (DA) and 
norepinephrtne (NE), durtng Infusion of selective monoamine 
uptake Inhibitors, were determined in freely moving rats. The 
basal concentration of NE in the dialysate was 4.9 ± 0.3 pg/20 
pl. lntravenous admlnistratlon of 5 or 10 mgJkg of SKF 86466 
was associated wlth a transierlt inc:rease (30 min) of 2-fold 
(12 ± 1 pg/20 ,d; p < .05) and 8-fold (39 ± 3 pg/20 pl; p < .05), 
respectlvely, in dlalysate NE, whereas a 1-mgfkg dose had no 
effect. DA was not detected in basal dlalysates, but after the 
adminlstratlon of 5 or 10 mgJkg of SKF 86466, 3.9 ± 0.4 and 
6.4 ± 0.6 pg/20 pl, respectlvely, was present in the dialysates. 
The rnaxlmum increase in dialysate DA was reached 60 to 90 
min after SKF 86466. The DA was not derived from plasma 
Tbe function of the presynaptic alpluJ-2 adrenoceptors at 
central noradrenergic junctions has been demonstrated largely 
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because plasma NE was elevated after the 5 mgJkg dose of SKF 
86466 whereas no plasma DA was detected. ln order to deter-
mlne whether DA was present in noradrenergic nerve termlnals, 
the dopamine ß-hydroxylase Inhibitor SKF 1 02698 was admin-
istered (50 mgJkg i.p.). The Inhibitor decreased dialysate NE but 
DA was stin not detected in the dialysate. When SKF 86466 (5 
mgJkg t.v.) was adminlstered 4 hr after SKF 102698, DA ap-
peared in the dialysate but there was no lncrease in dialysate 
NE. Administration through the dialysis probe of the DA uptake 
Inhibitor, GBR-12909 (0.1 and 1 pM), dose-dependently ln-
aeased DA Ieveis to 5.7 ± 1.2 and 9.6 ± 2.8 pg/20 pl, respec-
tively. GBR-12909 had no effect on hippocampal NE. Desipra-
mine (5 and 10 pM) lncreased dose-dependently dialysate NE 
and lncreased DA concentrations to detectable Ieveis (2.7 ± 0.5 
and 3.5 ± 0.7 pg/20 ,d, respectively). These results suggest that 
the a/pha-2 adrenoceptors modulate both NE and DA release in 
the rat hlppocampus and that DA detected in the hlppocampal 
dialysate might be released from dopaminergic neurons. 
by in vitro studies. Thus, it is well established that alpha-2 
adrenergic agonists inhibit the release of NE from nerve end-
ings (Langer, 1981; Schaffelmeer and Mulder, 1983; Duboco-
vich, 1984; Jackisch et al., 1984), whereas alpha-2 adrenergic 
antagonists enhance the release of NE (Dubocovich, 1984; 
Jackisch et al., 1984). These observations support a role for 
presynaptic alpha-2 autoreceptor-mediated inhibition in the 
physiological regulation of NE release. Tbe hippocampus re-
ceives a moderate NE innervation from the nucleus locus 
coeruleus via the fimbria-fomix, cingulus and the ventral amyg-
daloid bundles (Foote et al., 1983; Swanson et al., 1987; Oles-
kevish et al., 1989), and appears to have at least four subtypes 
A88AEVIATIONS: NE, noreplnephrlne; DA, dopamlne; SKF 86466, 6-chloro-2,3,4,5-tetrahydro-3-methyi-1-H-3-benzazepine; GBR-12909, 
1-{2-{bls(4-ftuorophenyl)methoxy~~3-phenylpropyl)plperazine dlhydrochlorlde; DHBA, 3,4-dlhydroxybenzylamlne; HPLC, hlgh-pressure liquid 
chromatography; DOPAC, 3,4-dlhydroxyphenylllcetlc ac:id; HVA, homovanilic acid; SKF 102698, 1-(3,5-difluorobenzyf)imidazole-2-thione; ANOVA, 
analysls of variance. 
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of adrenocepton (alpha-1, alpha-2, beta-1 and beta-2) (Swanson 
et al., 1987). Furthermore, the hippocampua receives dopami-
nergic afferent& from both A9 and A10 cell groups in the ventral 
tegmental area (Scatton et al., 1980), but the DA concentration 
in hippocampua is low (Biachoff et al., 1979; Vemey et al., 
1985), and it has been conaidered only to repreaent a NE 
precursor pool. However, there is evidence that DA acts as a 
neurotransmitter in hippocampua, independently of noradre-
nergic neurons (Bischof! et al., 1979; lshikawa et al., 1982; 
Vemey et al., 1985). 
Extracellular Ievels of monoamines in the hippocampua have 
been studied by in vivo microdialysis techniques (Abercrombie 
et al., 1988; Kaien et al., 1988; Abercrombie and Zigmond, 1989; 
Globus et al., 1989). Stimulation of the presynaptic alpha-2 
adrenocepton inhibited the hippocampal releaae of NE whereas 
alpha-2 adrenoceptor antagonists increased releaae (Abercrom-
bie et al., 1988). We monitored catecholamine releaae in hip-
pocampal dialysates of the conacioua rat after systemic admin-
istration of the aelective alpha-2 adrenoceptor blocker SKF 
86466. SKF 86466 is a cyclic derivative of phenylethylamine 
and a aelective alpha-2 adrenoceptor antagonist (Hieble et al., 
1986; Daly et al., 1988). Unlike idazonn, SK.F 86466 does not 
bind to imidazole sites in the rat brain (Emsberger et al., 1990). 
Furthermore, SKF 86466 does not significantly interact with 
dopaminergic, beta adrenergic, serotonin or musearlnie recep-
ton (Hieble et al., 1986). This drug has no known effect on 
dopamine metabolism and a very weak affmity for DA receptors 
(the IC150 of SKF 86466 for [1H]spiroperidol binding in rat brain 
homogenates and for DA-sensitive adenylate cyclaae in rat 
caudate is 10 ~&M (Dr. P. Hieble, personal communication). In 
our preliminary studies, SKF 86466 increased hippocampal NE 
releaae in a doae-dependent manner. We also detected DA in 
the hippocampal dialysate of SKF 86466-treated rats. To elu-
cidate the functional significance of alpha-2 adrenocepton in 
hippocampal adrenerpc tone, we studied DA and NE releaae 
into hippocampal dialysates obtained under basal conditions 
and after alpha-2 adrenergic blockade by intravenoua admin-
istration of SKF 86466 in conacioua rats. To elucidate further 
the source of DA in the hippocampal dialysate, the animals 
were treated with a DA ß-hydroxylaae inhibitor before SKF 
86466 administration. In addition, we determined whether ae-
lective local inhibition of the DA transporter would result to 
DA release from dopaminergic nerves projecting to the hippo-
campus. Forthis purpoae, we monitored hippocampal extracel-
lular catecholamine Ievels during local intrahippocampal infu-
sion through the dialysis tubing of GBR-12909, a aelective DA 
uptake inhibitor (Heikkila and Manzino, 1984; Anderaen, 
1989). For comparison, the catecholamine releaae was also 
monitored during infusion of the NE uptake inhibitor, desipra-
mine (Heikkila and Manzino, 1984). 
Materlai and Methods 
Male Sprague-Dawley rata (260-340 g) were uaed in all uperimenta. 
After the aurgical operationa, the rata were houaed individually in 
plaatic cagea (21 X 27 X 16 cm, W X L X H) with food and water ad 
libitum. In the end of the experiment they were aacrificed with an 
overdoae of pentobarbitsl. 
Dlalyal• Loop Prepa,.tion end Celibrlltlon 
A dialyaialoop waa conatructed from a 1.0-cm piece of hoUow dialyaia 
fiber with a molecular weight cutoff of 5,000 (Nephroaia Allegro H.F., 
Organon Teknika Corp, Durham, NC). A 1.5-cm length of Diebrome 
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wire (A-M System) waa inaerted into the fiber. Uaing the wire aa a 
guide, each end of the dialyaia tubing waa inaerted into a 2.5-cm length 
of capillary tubing (All Tech Asaociatee Inc., Deerfield, IL) to the depth 
of 2.0 mm and glued into place with cyanoacrylate adheaive (Elmer'a 
Wonderbond Plua). After the adheeive bad dried, the dialyaia fiber waa 
bent into a loop. A 16-puge atainleaa ateel tubing was placed over the 
free enda of the capillary tubing and poaitioned juat 2 mm above the 
dialyaia loop, where it waa glued with adheeive cyanoacrylate allowinJ 
4 mm uchangeahle aurface for dialyaia. 
The in uitro recovery of DA and NE were determined for each probe 
aa followa. Filtered artificial cerebroepinal fluid (147 mM NaCI, 4.0 
mM KCI and 2.30 mM CaCI1; pH adjuated to 7.0 with NaHCOa) waa 
perfuaed thro\llh the probe at 1 1'1/min with a CMA/100 microinjection 
pump. The recovery waa aaaeeaed in a beaker of the artificial cerebro-
apinal fluid aolution to which 10 ng/ml atsndarda of DA and NE bad 
been added. The amount of DA and NE in the perfuaatee were directly 
compared to that in the buffer. The in uitro recoveries were 24.6 ± 1% 
for DA and 25.0 ± 3% for NE. The valuea reported here are not 
corrected for theae recoveriea. 
Studl81 wlth the Alpha·2 Adrenoceptor Antegoni•t, 
SKF8M88 
Aalmal proceduree. The nta were aneathetized with an intramua-
cular injection of ketamine (130 mg/kg) and acepromazine (1.3 mg/ 
kg). In experimenta in which plasmawas aampled, PE-50 cathetera 
were inaerted into the left femoral vein and artery (pluma aampling 
experiment only). The cathetera were tunneled under the back akin 
and exteriorized at the nape of the neck. The rat was then mounted on 
a atereotuic apparatua (David Kopf lnc., Tujunga. CA). The akull wu 
expoaed and a amaU hole waa driUed to allow implantation of the 
dialyaia probe into the dorsal hippocampua uaing the coordinatea: 
anteropoaterior, -4.2 mm; mediolateral, -2.0 mm relative to bregma 
and vertical, -4.0 mm relative to dura with inciaor bar aet at -3 mm 
from horizontal zero. The dialyaia probe was flXed on the akull with 
two acrewa and dental cement and artificial cerebrospinal fluid was 
continuoualy perfuaed through the probe at a rate of 1 1'1/min. Tbe 
animal was allowed to recover for 4 hr alter the implantstion and 
perfuaate waa coUected in conacioua freely moving rata in 30-min 
fractione into a mini-vial containin1 30 PI of DHBA in 6 "1 of 0.1 N 
perchloric acid. The fractiona were coUected before and after femoral 
vein injection of either aaline or SKF 86466. 
Experimental protocola. All treatment groupe were independent 
and each rat received only one injection of aaline, artificial cerebroepi-
nal fluid or one doae Ievel of drup. 
DoN-ra.poue R11dlee. After coUection of two 30-min baae-line 
aamplea, aaline or 1, 5 or 10 mlfkg of SKF 86466 was injected intra-
venoualy at 120-min intervals. The perfuaate waa collected at 30-min 
intervals alter aaline or drug adminiatration. 
Time-ra.poue ltudiee. After collection of the two baae-line aam-
plea, aaline, SKF 86466 at doaea of 6 or 10 mg/kg or idazo:un at doaea 
1 or 5 mg/kg was injected intravenoualy and 30-min portiona of the 
perfuaate were coUected for 240 min. 
Pluma IIILIDpling. In a separate group of rata, blood apecimena 
were coUected aimultsneoualy with the perfuaate aamplea. The blood 
aamplea (0.8 ml) were withdrawn from the arterial catheter at 30-min 
intervals alter the adminiatration of SKF 86466 (5 mg/kg i.v.). The 
blood withdrawn waa replaced with an equal volume of freah rat blood. 
The blood apecimena were coUected in chilled teat tubea, centrifupd 
(Beckman microfuge B) i.mmediately for 1 min and tbe plaama removed 
and rapidly frozen on dry ice. NE and DA were aeparated by alumina 
extraction and aaaayed by HPLC as deacribed below. 
Treatment with the clopamlne ß-hydrosylue lDhibltor. The 
dopamine P-hydroxylaae inhibitor SKF 102698 (50 mg/kg) or vehicle 
(10% dimethyl aulfoxide in diatilled water) waa injected i.p. 4 hr before 
the i.v. injection of SKF 86466 (5 mg/kg). The hippocampal perfuaate 
and plaama aamplea were collected at 30-min intervala during the 
e:z:periment and proceued aa deecribed above. 
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StudiH with Ht~m.-llnfualon of 
DA or NE Uptake Inhibitors 
Tbe rata were aneathetiztd with an intramUICUlar injec:tion of keta-
mine (130 mgfkg) and acepromuine (1.3 ~n~/kc) and the microdialyaia 
probe guide cannulu were implanted 20 to 24 br before the uperimenta 
uaing atereotuic coordinatea anteropoeterior, -4.2 mm and mediola-
teral, -2.0 mm relative to bregmL Vertical depth wu 4.0 mm relative 
to the dural aurface. 
In the beginning of the experiment a microdialyaia probe (CMA/12, 
2 mm membrane, Bioanalytical Syatema, Inc., West Lafayette, IN) wu 
inatrted in the bippocampua tbrough tbe ,Wde cannula and perfuaed 
with artificial cerebroepinal Ouid at a rate of 1 ,d/min for 2 br before 
atarting the collection of perfuaate in 30-min fractiona. One bue-line 
aample wu collected before drug adminiatration. GBR-12909 (0.1 or 
1.0 ~&M) and deaipramine hydrocbloride (5 or 10 ~) were perfuaed 
tbroup the microdialyaia probe for 4 br. Tbree aamplea were collected 
after ceuation of drug infuaion. Tbe control group wu perfuaed with 
artiticial cerebroapinal Ouid 
Tbe rata were allowed to move freely during experimenta. In the 
end of the experiment they were aacriticed with an overdoae of 
pentobarbital. 
Aulylia of dialyü I&IDPI•. Tbe dialyaate (20 ~&I) was injected 
into an HPLC ayatem equipped with a 7 cm x 4.6 mm 3 ~&M reverae 
phaae ODS column, an amperometric detector and a glauy carbon 
elec:trode (Water'a 460 Electrochemical detector, Milford, MA) aet at 
0.60 V relative to a Ag-A,cl reference electrode. Tbe mobile phaae 
contained 50 mM aodium ac:etate, 20 mM citric acid, 2 mM octane 
aulpbonate, 0.1 mM ethylenediaminetetraacetic acid, 0.1 mM butylam-
ine and 10% (v/v) metbanol, at pH 4.7. Tbe mobile phaae wu filtered 
throUJh a 0.22 ~&M tilter and depued under vacuum by meana of 
ultruonic agitation. AU aeparationa were performed iaocratically at a 
Oow rate of 1 ml/min. Tbe temperature of the column was kept at 38"C 
by meana of a column heater. DA and NE concentrationa were corrected 
for the recovery of DHBA and were expreued u pg/20 ~&I of perfuaate. 
Tbe aenaitivity of the metbod was estimated from the amount of tbe 
compound whicb givea a peak beigbt 2 times that of bue üne and was 
2 pg for DA and 1.5 PI for NE. Tbe authenticity of DA and NE in the 
aamples wu veritied by parallel cbromatograpbic and radioenzymatic 
aaaaya of aelected dialyaate apecimena (table 1). Catecbolamine concen-
trationa were meuured by a catecbol-0-methyltranaferaae-baaed 
radioenzymatic tecbnique (Da Prada and Zürcher, 1976). 
In the intrahippocampal infiaion experimenta, DA, NE, DOPAC and 
HV A concentrationa in the dialyaate were analyzed uain1 HPLC with 
electrochemical detection (Waten 460) u described above. In theae 
atudiea, tbe mobile phaae was aligbtly modified to improve aeparation 
and increaae aenaitivity, and contained aodium acetate 80 mM, octyl 
aodium aulphate 0.90 mM, EDTA 0.1 mM, citric acid 70 mM and 
acetonitrile 4.9% (v/v), pH 2.9 to 3.0. AU aeparationa were made 
iaocratically at a Oow rate of 1 ml/min at 38"C. Tbe aenaitivity of the 
ayatem wu estimated u the amount of the compound giving a peak 
beigbt 2 time• that ofbaae-line noiae, and was 2.0 PI for DA, 1.0 PI for 
TABLE 1 
eom,.rteon of ......... Md norep~~..,-... C01antr'8tlon81n .... 
hippoc8mpiii...".....IMIIeurHin ....... by eilher hlgh-
preauNIIquld chromatogr.phy (HPLC) or NdloenzytMtlc a ... y 
(REA) 
A ~,.1 voune of perfulate wu callected after lntravenoullnjection of SKF 8&486 
(5mglkg). ll*ty rricrollterl wu lr1ected lnto lht HPLC aystem, lnd lht rwnalr*1g 
eo ,.. Wll uuyed w1tt1 ~ method. Atlln'Yiatlol•: BLD, bllow lht 
lrnlt d detec:llon (1.5 pg/20 ,.1). 
1 
2 
3 
4 
tfiLC 
4.0 
2.4 
2.1 
3.1 
REA 
5.2 
2.8 
2.3 
3.1 
tfiLC REA 
2.3 1.1 
2.6 2.8 
BLO 0.3 
4.5 3.0 
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NE and DOPAC and 4.0 PI for HVA. In uitro recoveriea (%) were 
25 ± 1 for DA, 25 ± 2 for NE, 28 ± 2 for DOPAC and 33 ± 2 for HVA. 
The reaulta are not corrected for theae recoveriea. 
Hlatology 
Tbe brainl were quickly removed and frozen on dry ice. Coronal 
aectiona (50 ~&M) of forebrain were cut on a cryoatat and atained witb 
0.1% thlonin. Hiatologicallocalization of the microdialyaia probe wu 
veritied accordin1 to a atereotuic atlaa (Puinoa and Wataon, 1986). 
Our previoua atudiea demonatrated only minimal damage of hippocam-
pal neuronal cell bodiea 24 br alter implantation of tbe loop probe 
(Shuaib et a.L, 1990). 
DrugaUaed 
Tbe aelective alpluJ-2 adrenoceptor antagoniata, SKF 86466 (Hieble 
et a.L, 1986; Daly et a.L, 1988) and idazoun [2-(2-(1,4 benzodioxanyl))2-
imidazoline bydrocbloride; Dolley et a.L, 1983) were diaaolved in aaline. 
SKF 102698, a competitive and aelective dopamine ß-hydroxylaae in-
bibitor (Berkowitz et a.L, 1988), wu di.uolved in 10% dimetbylaulfoxide 
in diatilled water. GBR-12909, 1 aelective blocker of DA uptake (Heik-
kila and Manzino, 1984; Anderaen, 1989), and the NE uptake inhlbitor, 
deaipramine bydrocbloride (Heikkila and Manzino, 1984) were dia-
aolved in artificial cerebroapinal Ouid Tbe pH of the drug aolutions 
was6to 7. 
Statlatical Analyata of the o ... 
Data in te:rt and (~~Ufea are repreaented as mean ± S.E.M. for the 
indicated number of rata. For atatiatical analyaia tbe CSS:atatiatica 
aoftware package (StatSoft, Inc., Tulaa, OK) wu uaed. Statiatica were 
calculated uain1 two-way ANOVA with repeated meaaurea, one-way 
ANOVA with a poat-boc Student·Newman-Keul'a test or for data witb 
unequal variances tbe nonparametric Kruakal-Wallia ANOVA witb 
Mann-Wbitney U-teat or the Wilcollon matcbed paira teat. For atatia-
tical purposea, when DA and NE concentrationa were below detection 
ümit, valuea of 1.99 and 1.49 pg were uaed, reapectively. 
Results 
The basal amount of NE averaged 4.4 ± 0.5 pg/20 1'1 of 
perfusion. Thia basal Ievel was not changed by the lower dose 
of 1 mg/kg dose of SKF 86466. SKF 86466 at doses of 5 and 10 
mg/kg increaaed e:rlracellular Ievels of DA and NE in the rat 
hippocampua dose-dependently (fig. 1). Administration of 5 
and 10 mg/kg of SKF 86466, was 8880Ciated with an increase 
in dialysate NE of about 2-fold (11 ± 1 pg; P < .05) and 9-fold 
(39 ± 3 pg; P < .05), reapectively. DA was not detected in baae-
line samplea but after the adminiatration of 5 or 10 mg/kg of 
SKF 86466, dialysate DA concentrationa were 3.9 ± 0.4 and 
6.4 ± 0.6 pg, respectively (fig. 1). An increase in DA Ievel (6.4 
± 3.5 pg; P < .05) was also aeen after intravenoua administra-
tion of idazoxan (5 mg/kg; n • 3). 
The time course of the increaae in dialysate DA and NE after 
the adminiatration of SKF 86466 is shown in figure 2. The 
increase in NE reached a muimum in the fll'lt 30-min fraction 
after drug adminiatration and then retumed to base line within 
90 to 120 min. By contrast, the muimum increase in dialysate 
DA was reached 90 min after administration of the 5 mg/kg 
dose of SKF 86466 and subsided in 150 min. After the 10 mg/ 
kg dose, the peak increaae was achieved 60 min after drug 
administration and DA was detectable at least 300 min. 
Effect of SKF 88<&66 on plaama catecholamiDes. 
Plasma NE was 195 ± 53 pg/ml (n = 4) at base line. Intravenoua 
administration of SKF 86466 (5 mg/kg) increased plasma NE 
by more than 20-fold (fig. 3). The muimum Ievel of plasma 
NE (4275 ± 1295 pg/ml) was reached 60 min after the drug 
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Flg. 1. Dose-response effect of SKF 86466 on dlalysate DA and NE 
ooncentrations in the rat hippocampus. The vaJues on the ordNte ere 
the maxlmum concentrations of catecholamines, mean ± S.E.M. The 
number of rinals in the base llne (1) and sallne (2) control groups was 
slx, whereas the SKF 86466 (1 mgJkg) group (3) had 11 rats, SKF 86466 
(5 mgjkg) group (4) h8d 14 rats and the SKF 86488 (10 mgjkg) group 
(5) had four rats. *Differs from base Une, P < .05 (Student Newman-
Keul's test); BLD, below the lmit of detection. The broken llne (-) 
lndicates the Iimit of detection (2 pgJ20 ,d for DA and 1.5 pg/20 ,d for 
NE). Dialysate DA was below the IImit of detection (BLD) at base lne 
(1), after sallne adrmstration (2) and after the 1 mgJkg dose of SKF 
86466(3). 
injection. In contrast to the hippocampus wbere NE rapidly 
retumed to base-line Ievels, the circulating Ievels of NE were 
elevated by more tban 10-fold during the 240-min monitaring 
period. Plasma DA was not detected at base line or at any time 
after administration of SKF 86466. 
Inlluence of the DA ß-hydroxylue Inhibitor. The pos-
aibility that DA was preaent in the bippocampal dialyaate as a 
precursor of hippocampal NE was inveatigated with the DA ß-
hydrozylase inhibitor, SKF 102698. Intraperitoneal injection 
of 50 mg/kg of SKF 102698 was asaociated with a reduction in 
hippocampal dialyaate NE below the limit of detection. DA was 
not detected in the hippocampal perfuaate (fig. 4). SKF 86466 
(5 mg/kg i.v.) administered 4 hr after the dopamine P-hydrox-
ylase inhibitor increaaed dialyaate DA in the 60-min fraction 
of the hippocampal perfusate but bad no effect on dialyaate 
NE (fig. 4). 
Treatment with SKF 102698 effectively inhibited the DA ß-
hydroxylase, because plasma NE declined from the base-line 
concentration of 410 :t 40 pg/ml (n - 6) to 280 :t 80 pg/ml 4 
hr after SKF 102698 adminiatration. Plasma DA was increaaed 
from undetectable to 180 :t 60 pg/ml (n • 6; P < .05 compared 
to base line). When SKF 86466 was adminiatered in two rat& 
treated with the DA ß-hydrozylase inhibitor, plasma DA was 
increaaed to 3140 and 3850 pg/ml, reapectively, and plasma NE 
was increaaed to 4005 and 2950 pg/ml, respectively. 
Local hippocampal inluaion oflnhibiton of DA or NE 
uptake. DA was not detected at base line or any of the aamples 
from the control group that was infused with vehicle (artificial 
cerebroapinal fluid). Base-Une Ievels for NE were 4.9 :t 1.1 pg/ 
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Flg. 2. DA and NE concentratlons in the rat hlppocampus at varlous 
t1mes after admlnlstratlon of SKF 86466. The arrow denotes the tntra-
venous lnjection of SKF 86466 or sallne vehlcle. The samples were 
collected at 30-mln intervals. The ordnates glve catecholamlne conoen-
tratlons as mean ± S.E.M. The mrnber of .wnaJs in the sallne control 
group and in the SKF 86488 (10 mgJkg) groups was br. in the SKF 
86488 group 1t was three . The broken lne (-) lndicates the IImit of 
detection (2 pgJ20 ,d for DA n:l 1.5 pgJ20 p.l for NE). DA was not 
detected at any time point after sallne admlnlstration. For statistlcal 
analysis, the data polnts representlng the anples below the lmit of 
detactlon for DA were asslgned an arbitrary value (1.99 pg/20 ,.J). The 
effecta of both SKF 86488 dole8 were slgnlflcantly dffwent from sallne 
(~way MANOVA wlth repeated me&SU'88; tineJtreatment). DA 5 
mgjkg dose, F • 7.46, P • .0002; 10 mgJkg, F • 8.09, P • .0001; 
NE, 5 mg/kg dose, F • 7.89, P • .0001; 10 mg/kg dose, F • 95.13, 
P< .00001. 
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Flg. 3. Change& in plasma NE concentration after the lntraYa'WS 
injection of SKF 86488 (5 mg/kg). SKF 86466 or sa11ne was injected at 
the time denoted by the arrow. The ordlnate glves NE concentratlons as 
mean ± S.E.M. The runber of anlmaJs in the SKF 86466 group was 
four, in the aallne group lt was ftve. NE c:onc:entratlona after SKF 86486 
dtffared aignificantly from saht-treated controls (two-way MANOVA wlth 
repeated measures; tineftreatment F - 4.90, P < .01 ). 
20 pl, and were not affected by the vehicle infusion (fig. 5, C 
andD). 
Hippocampal perfusion with 0.1 and 1 pM GBR-12909 doae-
dependently increaaed DA Ievels (fig. 5A) up to 5. 7 :t 1.2 
(mean :t S.E.M.) and 9.6 :t 2.8 pg/20 pl, respectively. DA 
appeared in the first collection fraction during the drug perfu-
aion and stayed at high Ievels during the 4-hr perfuaion. When 
the drug was withdrawn, DA concentrations decreased dramat-
ically, but remained detectable throughout tbe 90 min period 
after drug perfusion. 
DA was also detectable during perfusion with 5 and 10 p.M 
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Flg. 4. Effact of SKF 86466 (5 mgJkg l.v.) an dalysate NE and DA 
COIICelitratioiiS in rats PI etJ eated wlth the doparnine IJ-hydroxytase lnhl~ 
ltor, SKF 102698. SKF 102698 (50 rngJkg l.p.) waslnjected 4 hr before 
SKF 86466. (1) lndlcates basellne, (2) lndcates treatment wlth the 
doplmlne p.hydroxylase Inhibitor, SKF 102698 and (3) lndicates com-
blned traatment wlth SKF 102698 end SKF 86466. Values are given as 
mean :t SEM. For meauement of dialysate DA (the upper panel) each 
group comprtsed flve rats, for rneas&nment of c:lelysate NE (lower penel) 
the bue-lne ll'ld SKF 102698 groupa hlld eight rats whereas the third 
(SKF 102698 + SKF 86486) group hed ftve rats. The broken llne (-) 
lndlcates the Hmlt of detection 2 pgJ20 pJ for DA and 1.5 pg/20 "1 for NE. 
"'Offers from basellne, P < .05 (Mam-Whltney ~test); BLO, be1ow the 
IImit of detectlon. 
desipramine ((tg. 58). Tbe muimum, 3.5 ± 0.6 pg/20 pl, was 
reached at the end of perfusion with 10 pM desipramine. 
Desipramine increased NE Ievels in a dose-dependent man-
ner (fig. 50) to 8.7 ± 1.4 pg/20 ~&I (5pM) and 14.1 ± 1.7 pg/20 
pl (10 pM). There wen no significant changes in NE Ievels 
after GBR-12909 (fig. 5C) nor in concentrations of DOPAC or 
HV A in any of the experimental groups (not shown). 
Dlscussion 
The basal enracellular concentration of NE (4.3 ± 0.3 pg/ 
20 pl) in our study was comparable to findings in previous 
studies in which NE release in rat hippocampus was estimated 
by microdialyais (Abercrombie et al., 1988; Kalen et al., 1988; 
Abercrombie and Zigmond, 1989). The administration of SKF 
86466, an alpha-2 adrenoceptor antagonist, was associated with 
an increase in dialyaate NE in a dosa-dependent manner with 
a rapid but relatively sbort-lasting time courae. The increase 
in dialyaate NE was not a reßection of changes in plasma NE 
because Ievels in the plasma were increased for more than 2-hr 
after SKF 86466 administration. The data a.re compatible with 
the hypothesis that presynaptic alpha-2 adrenoceptors regulate 
NE releaae in the hippocampua. The data a.re similar to rmdings 
after the administration of yohimbine, another alpha-2 adre-
noceptor antagonist (Abercrombie et al., 1988). 
DA could not be detected in the base line or after adminis-
tration of 1 mgfkg of SKF 86466, but it appea.red in the 
dialyaate alter administration of SKF 86466 (5 and 10 mg/kg). 
To be certain that this peak represented DA, dialyaate samples 
DA and NE A ...... ln Hlppocempu8 215 
were analyzed by HPLC and the radioenzymatic 8888Y in 
parallel with compatible reaults. Moreover, the retentiontime 
of the DA peak of the dialyais aample was identical with that 
of the standard DA peak when eluted with two different mobile 
phases. Tberefore, the peak in the HPLC aamples represents 
DA coming from the hippocampua. The pouibility that circu-
lating DA contributed to DA found in the hippocampal perfua-
ate was excluded because DA was never above the Iimit of 
detection in the plasma samples. 
The peak values of NE and DA after SKF 86466 treatment 
emerged at different dialysate fraction. The peak value of NE 
appeared at the rll'8t 30-min aample fraction and the Ievels 
retumed back to base-line values within 90 min after the 
administration of SKF 86466. In contrast, DA in the dialyaate 
reached maximum Ievels 60 min after administration of SKF 
86466 and remained elevated throughout the collection period. 
The differential time-respoll8e of tbe increases in dialysate DA 
and NE may aupport the concept that DA and NE in the 
hippocampal dialyaate have been released from separate ter-
minal& and thus DA detected in the hippocampal dialysate has 
not been derived from noradrenergic terminals but has been 
released from diatinct dopaminergic neurons. However, the 
sustained release of DA could, at least in part, retlect overtlow 
of DA which has been taken up from the enracellular apace 
into the noradrenergic terminals as DA exhibita high aff'mity 
for the NE carrier (Raiteri et al., 1977) and extracellular do-
pamine can be taken up into noradrenergic terminala (Carboni 
et al., 1990). 
The hippocampua is innervated by dopaminergic fibers (Bis-
choff et al., 1979) originating from the ventral tegmental area 
and the aubstantia nigra (Scatton et al., 1980; Swanaon et al., 
1987). The presence of speci.fic hippocampal DA receptors has 
been demonatrated by pharmacological, electrophyaiological 
and radioligand binding techniques (Swanson et al., 1987). 
However, there are only few DA neurona in the hippocampus 
and tiuue Ievels of DA are low (Bischoff et al., 1979; Vemey et 
al., 1985; Lategan et al., 1992). Accordingly, DA was not de-
tected in any of the base-line aamples, which is in agreement 
with earlier studies (Abercrombie et al., 1988; Bhardwaj et al., 
1990), but was only seen after treatment with the alpha-2 
adrenoceptor antagonists or monoamine uptake inhibitors. In 
agreement with our data, DA was detected in the dialyaates of 
gerbil hippocampua alter induction of forebrain iachemia by 
ligation of the carotic arteriea (Bhardwaj et al., 1990). Because 
we verified the placement ofthe dialyais probe in the hippocam-
pus in all animals, DA in dialysates moat likely came from 
hippocampal sources. Therefore, it does not seem likely that 
diffusion from other brain regions would have aignificantly 
contributed to the DA detected in the hippocampal dialyaates. 
Several eitee and mechaniema of action could account for the 
SKF 86466-induced DA releaae in hippocampua. Pharmacolog-
ical studies bave demonstrsted the existence of alpha-2 adre-
noceptor mediated inhibition of DA release in dopaminergic 
terminals in retinal neurons (Dubocovich, 1984) and in the 
hypothalamus (Ueda et al., 1983). The alp#w-2 agoniat clonidine 
inhibited the evoked release of DA from rabbit retina in a doae-
dependent manner whereas yohimbine, an alphtJ-2 adrenocep-
tor antagonist, completely antagonized the inhibitory effect of 
clonidine (Dubocovich, 1984). Administration of yohimbine, 
increased brain DA tumover (Papeschi and Theias, 1975; 
Anden and Grabowska, 1976) presumably by an indirect action 
of yobimbine exerted through changes in NE neurotransmis-
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sion (Anden and Grabowska, 1976). We speculate that SKF 
86466 increased DA release in the hippocampua resulta from a 
similar mechanism. Becauae SKF 86466 has ahown to be a 
selective a/pha-2 adrenoceptor 8Dtagonist (Hieble et al., 1986; 
Daly et al., 1988) with only weak activity at dopaminergic 
recepton (Dr. P. Hieble, personal communication), the poui-
bility that theee effects are mediated by blockade of presynaptic 
dopamine autoreceptors ia unlikely. Furthermore, idazo:un, 
8DOther aelective a/pha-2 8Dtagoniat, which has a very low 
affmity for DA recepton (Walter et al., 1984), also increased 
hippocampal DA Ievels. Consequently, the detected DA release 
may be elicited by blockade of alpha-2 adrenoceptors. 
The hippocampal DA might also derive from noradrenergic 
terminals where it serves as a precursor to NE aynthesis 
(Brownatein et al., 1974; Lindvall et al., 1974; Westerink 8Dd 
Devries, 1985). lf release from noradrenergic terminals bad 
been the major source of DA in the present study, however, 
hippocampal release of DA ahould have been enhanced in rats 
treated with the DA tJ-hydros:ylase inhibitor becauae thia drug 
effectively inhibited the formation of NE in the noradrenergic 
neurons. On the contrary, our results demonstrated that the 
DA tJ-hydros:ylase inhibitor did not affect basal hippocampal 
DA release. Furthermore, SKF 86466-induced release of hip-
pocampal DA was not inßuenced by prior treatment with the 
DA tJ-hydros:ylase inhibitor conaiatent with DA release from 
dopaminergic nerve terminals. In agreement with theae data, it 
has been recently demonatrated that treatment of rata with the 
noradrenergic neurotoxin N -(2-chloroethyl)-N -ethyl-2-bromo-
benzylamine resulted in a siplificant depletion of NE in the 
hippocampua without significantly affecting hippocampal DA 
levela or DA content of the caudate nucleua (Lategu et al., 
1992). 
150 210 270 330 
timP (min' 
Further support for DA release from dopaminergic terminala 
in the hippocampua was furnished by the findinp that local 
administration ofGBR-12909, a selective DA uptake inhibitor, 
through the in vivo microdialyaia tubing doee-dependently in-
creased DA in hippocampal dialyaatea but bad no aipificant 
effect on dialyaate NE levela. Deeipramine, a potent inhibitor 
of NE uptake 8Dd a weak inhibitor of DA uptake (Heikkila and 
Manzino, 1984; Shimada et al., 1991), increased mainly dialy-
sate NE concentrations. GBR-12909 ia a potent and hichly 
selective DA uptake inhibitor with no effect on NE uptake 
(Heikkila 8Dd Manzino, 1984; Andersen, 1989) 8Dd it haa high 
affinity for a recently cloned dopamine transporter (Shimada 
et al., 1991). In the striatum, locally applied GBR-12909 in-
creased DA concentrations (Nomitoe et al., 1990). Hieb con-
centrations of GBR-12909 were reported to directly releaae DA 
(Nomikoa et al., 1990). Doeea of GBR-12909 uaed in our exper-
iment are in a r8Dge where it acta as a pure DA uptake inhibitor 
8Dd has no marked affinity for other known carriera or recep-
tors (Andersen, 1989). Baaed on the selectivity of GBR-12909 
for the DA transporter (Andersen, 1989; Shimada et al., 1991) 
and the marked difference between the effecta of GBR-12909 
8Dd desipramine on monoamine Ievels in the present experi-
ment we conclude that the GBR-12909 induced increue in 
dialysate DA resulted from inhibition of DA transport Bites in 
dopaminergic terminals. 
The sharp onset 8Dd otüet of the increaae in dialyute DA 
during GBR-12909 infuaion indicated that GBR-12909 prob-
ably acted on uptake aitea different from the aitea on noradre-
nergic terminals which were blocked by deaipramine. The time 
course of the appearance of DA in the hippocampal dialyaate 
as well u the magnitude ofDA increase after deeipramine were 
different from those elicited by infuaion with the eelective DA 
1993 
uptake inhibitor. The gradual increase in dialysate DA during 
duipramine perfusion demonatrated, however, that the abun· 
dant noradrenergic terminals in the hippocampua could serve 
88 an additional aource for extracellular dopamine. During 
deaipramine infuaion, a profound dose-dependent increase in 
dialyaate NE preceded the auatained increaae in dialyaate DA 
augeating that the eztracellular DA detected after desipramine 
infusion derived from noradrenergic terminals. Thia poaaibility 
ia aupported by the findinp that DA e:dlibita high affmity for 
the NE carrier (Raiteri et aL, 1977) and that in NE-rieb brain 
ueu auch 88 the prefrontal cortez, enracellular DA can be 
taken up into noradrenergic terminals (Carboni et aL, 1990). 
However, it could also be posaible that deaipramine at the 
relative high doaes used in the present study could have inhib-
ited DA uptake in dopaminergic terminals (Heikkila and 
Manzino, 1984; Shimada et aL, 1991). 
In concluaion, the preaent atudy ahows that 1) intracerebral 
microdialyaia provieles a useful method to monitor enracellular 
DA and NE Ievels in the hippocampal formation of the con-
scioua rat; 2) administration of SKF 86466 increased the release 
of NE in hippocampal eztracellular tluid emphasizing the fact 
that, in hippocampua, olpha-2 adrenocepton ezert important 
regulatory intluencea; 3) SKF 86466 increued the release of 
DA implying that olpha-2 adrenocepton may also regulate DA 
releue in the hippocampua and 4) aelective blockade of the DA 
uptake proceu by GBR-12909 rapidly increued hippocampal 
DA Ievels, with no aignificant changea in the amounta of NE 
or eecondary metabolitea. Based on theae rmdinp, we propose 
that DA may be releued directly from dopaminergic nerve 
terminale in the hippocampua. 
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